Based on the BioGaia AB ser. B stock forecast from 0 analysts, the average analyst target price for BioGaia AB ser. B is not available over the next 12 months. BioGaia AB ser. B’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioGaia AB ser. B is Very Bullish, which is based on 1 positive signals and 0 negative signals. At the last closing, BioGaia AB ser. B’s stock price was SEK 98.65. BioGaia AB ser. B’s stock price has changed by +6.43% over the past week, -2.13% over the past month and +25.30% over the last year.
No recent analyst target price found for BioGaia AB ser. B
No recent average analyst rating found for BioGaia AB ser. B
Company Overview BioGaia AB ser. B
BioGaia AB (publ), a healthcare company, develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; Helicobacter pylori"the gastric ulcer bacterium; low bone density; and diverticulitis, as well as baby and child gut, adult gut, immune, pregnancy, oral, and bone health. It offers its products under the BioGaia brand name. The company sells its products through distribution partners or through its own distribution channels. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden. Address: Kungsbroplan 3, Stockholm, Sweden, 112 27 Read Less
BioGaia AB (publ), a healthcare company, develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health ta...Read More
Frequently Asked Questions About BioGaia AB ser. B (0GTN:LSE) Stock
Stock Target Advisor's fundamental analysis for BioGaia AB ser. B's stock is Very Bullish.
0GTN:LSE stock's dividend yield is 0.01%.
Based on this 0GTN:LSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 0GTN:LSE's stock to indicate what its average analyst target is.
0GTN:LSE stock's Price/Earning ratio is 49.85.
Based on this 0GTN:LSE may be a overvalued for its sector.
The last closing price of 0GTN:LSE's stock was SEK 98.65.
The most recent market capitalization for 0GTN:LSE is SEK 9.77B.
Unfortunately we do not have enough analyst data on 0GTN:LSE's stock to indicate whether its price will go up or not.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
What not to like
There is nothing we particularly dislike
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 0GTN:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
